anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A rich and complex temporal structure of variability in postural sway characterizes healthy and adaptable postural control. However, neurodegenerative disorders such as Parkinson's disease, which often manifest as tremors, rigidity, and bradykinesia, disrupt this healthy variability. This study examined postural sway in young and older adults, including individuals with Parkinson's disease, under different upright standing conditions to investigate the potential connection between the temporal structure of variability in postural sway and Parkinsonism. A novel and innovative method called oriented fractal scaling component analysis was employed. This method involves decomposing the two-dimensional center of pressure (CoP) planar trajectories to pinpoint the directions associated with minimal and maximal temporal correlations in postural sway. As a result, it facilitates a comprehensive assessment of the directional characteristics within the temporal structure of sway variability. The results demonstrated that healthy young adults control posture along two orthogonal directions closely aligned with the traditional anatomical anteroposterior (AP) and mediolateral (ML) axes. In contrast, older adults and individuals with Parkinson's disease controlled posture along suborthogonal directions that significantly deviate from the AP and ML axes. These findings suggest that the altered temporal structure of sway variability is evident in individuals with Parkinson's disease and underlies postural deficits, surpassing what can be explained solely by the natural aging process.
On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.
Three monthly doses of R21/MM will be administered to all eligible residents in the 27 intervention villages (15 in The Gambia and 12 in Burkina Faso), starting from May 2024, with the aim of having completed the vaccination schedule by end of July 2024, before the malaria transmission season starts. A booster vaccine dose will be administered in June 2025 to all eligible individuals who received at least one vaccine dose the previous year. Residents who are eligible but not vaccinated in the previous year, will be offered a complete vaccination schedule, i.e. 3 monthly doses, starting from April. After each vaccination, the first 100 vaccinated individuals will be visited at home daily, for 3 consecutive days, and then at day 7 after the vaccination to collect local and systemic adverse events (AE). Vaccinated individuals (or their parents) will be asked to report to the nurse based in their study village any illness occurring during the 28 days after vaccination.
Coma caused by cerebral ischemia is the most serious complication of cerebral ischemia. Four-vessel occlusion can establish a cerebral ischemic coma model for disease research and drug development. However, the commonly used four-vessel occlusion method mainly involves inserting an electrocoagulation pen into the bilateral pterygoid foramen of the first cervical vertebra behind the neck to electrocoagulate the vertebral arteries. This process carries the risk of incomplete electrocoagulation, bleeding, and damage to the brainstem and spinal cord. Twenty-four hours after surgery, re-anesthetized rats undergo carotid artery ligation in front of the neck. Two surgeries expose the rats to a higher risk of infection and increase the experimental period. In this study, during a single surgical procedure, an anterior cervical incision was used to locate the key site where the vertebral artery penetrates the first cervical vertebra. The bilateral vertebral arteries were electrocauterized under visual conditions, while the bilateral common carotid arteries were separated to place loose knots. When the rats showed consciousness of the inversion reaction, the bilateral common carotid arteries were quickly ligated to induce ischemic coma. This method can avoid the risk of infection caused by two surgical operations and is easy to perform with a high success rate, providing a useful reference for relevant practitioners.
The present invention relates to a transformed stem cell capable of expressing GLB1 gene, and a pharmaceutical composition for G_M1 gangliosidosis or IVB-type mucopolysaccharidosis (MPS) treatment including the transformed stem cell. When a stem cell with transformed GLB1 gene is injected into the nasal cavity, the stem cell is transmitted to the nerve tissue in the brain and can express β-galaktosidase-1 enzyme. To be more specifically, the stem cell manufactured by the present invention can have an improved expression ratio of GLB1 gene by optimizing a gene introducing method and the type of a lentivirus expression vector. In addition, the stem cell can improve treatment efficiency by optimizing the number of cells inputted into the nasal cavity. Thus, it is verified that G_M1 ganglioside accumulated inside the nerve tissue in the brain is significantly reduced when the transformed stem cell capable of expressing GLB1 gene is injected into the nasal cavity of a G_M1 gangliosidosis causing mouse under the optimized condition. Therefore, the transformed stem cell capable of expressing GLB1 gene, and the pharmaceutical composition for G_M1 gangliosidosis or IVB-type MPS treatment including the transformed stem cell can be useful in treatment of G_M1 gangliosidosis or IVB-type MPS by well expressing β-galaktosidase-1 enzyme in the nerve tissue in the brain and effectively disintegrating G_M1 ganglioside accumulated in the nerve tissue in the brain.
This Phase 2 gene transfer study will look at whether different doses of Ad2/HIF-1α/VP16 can be tolerated safely by direct injection into the leg muscles where the blood flow is not sufficient to meet the oxygen demands of the leg muscles. The study will also assess whether patients who receive the investigational drug product are able to increase their maximal walking time using a standardized treadmill walking test.

The study design is a randomized, double-blind, placebo-controlled, parallel group, multi-center, Phase 2 dose-selection study. Seventy-five patients will be enrolled into each of 4 study drug groups (3 groups of Ad2/HIF-1α/VP16 gene transfer and 1 placebo group) for a total of 300 patients overall. Three different doses of Ad2/HIF-1α/VP16 gene transfer will be studied. The dose range was previously tested in animals and in the Phase 1 human studies. A placebo group is included in the study to compare safety and efficacy of different doses of Ad2/HIF-1α/VP16 with placebo. Each patient will receive a single set of 20 injections (100 μL each) of gene transfer or placebo in one administration to each leg for a total of 40 injections.
The invention relates to biotechnology, immunology and virology. The claimed agent can be used for the prevention of diseases caused by severe acute respiratory syndrome virus SARS-CoV-2. The technical aim of the claimed group of inventions is to create agents containing a single active component and along with this ensuring the effective induction of immune response to the SARS-CoV-2 virus among broad strata of the population. Solution of the technical problem is a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 26, wherein the El and E3 regions are deleted and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. Also, there is created a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of human adenovirus serotype 5, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. Further, there is claimed a variant of the agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in liquid form which contains, as a single active component, the expression vector based on the genome of the recombinant strain of simian adenovirus serotype 25, wherein the El and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3. At that, for the particular case of implementation, a buffer solution of the agent for liquid form contains the following, mass%: tris                           from 0,1831 to 0,3432 sodium chloride                from 0,3313 to 0,6212 sucrose                        from 3,7821 to 7,0915 magnesium chloride hexahydrate    from 0,0154 to 0,0289 EDTA                           from 0,0029 to 0,0054 polysorbate-80                 from 0,0378 to 0,0709 ethanol 95%                    from 0,0004 to 0,0007 water                          the remaining part. Each of the agent variants is used for inducing specific immunity against the severe acute respiratory syndrome SARS-CoV-2 virus. With that, the agent is intended for intranasal or intramuscular administration. Also, the agent can be administered concomitantly and simultaneously via intranasal and intramuscular routes.
The invention relates to the field of bioorganic chemistry, pharmaceutical chemistry and technology of drugs and concerns methods for producing preparations of vegetable raw material, which possess hepatoprotective activity. Technical result of the claimed invention is achieved by that the ecologically safe barothermal method is used for producing extract balsam poplar (Populus balsamifera L.) buds with pinostrobin flavonoid content of 0.9% with reference to air-dry raw material by extraction of raw material at a temperature of 150-160°C, pressure of 1.9 atm., for 60 min, separation and purification of thick extract by method of column chromatography with elution with petroleum ether and mixture petroleum ether-ethylacetate 49:1, recrystallisation of isolated technical pinostrobin with further synthesis of pinostrobin oxime (substance for pharmaceutical dosage form). Pinostrobin oxime substance is not toxic, does not cause acute toxic reactions in tests in mice and rats and demonstrates the high hepatoprotective activity in dose of 100 mg/kg of weight, and in the dose of 50 mg/kg eliminates manifestations of cytolysis, cholestasis and mesenchymal inflammation syndromes. Pinostrobin oxime relates to "short-living" products. In rat organism the product is revealed within 2 hours, irrespective of the administered dose and method of administration, penetrates well mainly in vascularised organs (kidneys, liver, lungs), and absolute bioavailability of pinostrobin oxide is 11%. Antioxidant activity of pinostrobin oxime is 20 times as high as that of pinostrobin. Pinostrobin oxime does not produce any toxic effect on the liver, reduces the lipoperoxidation intensity, the triacylglyceride content by 26% in it and increases phospholipid level by 21%, inhibits lipid peroxidation processes in hepatocytes, reducing diene conjugate content by 35%, increasing the activity of antiperoxide protection enzymes - glutathionperoxidase and glutathion reductase up to 54%.
PROBLEM TO BE SOLVED: To separate and collect solvent component and microparticle component continuously, by causing an ultrasonic wave to act in the direction perpendicular to the flow of the solution and making a suction port for collecting separated solvent or microparticles in the wall face. SOLUTION: An ultrasonic flow cell 60 is provided with resonant plates 151, 152 and shielding plates 161, 162 to form a sample solution channel. When the width of the channel is set equal to λ/2 or (λ/2+nλ) of the wavelength λof ultrasonic wave generated from ultrasonic oscillators 131, 132, an ultrasonic standing wave having a node of sound pressure at the center of the channel is generated. Here, n is an integer. A pipe for introducing a sample solution to the channel, a solvent component suction pipe 171 and a pipe 172 for leading out a concentrated solution of microparticles are provided. Suction port of the suction pipe 171 is sufficiently smaller than the wavelength λ and it does not disturb the sound field. The microparticles are subjected to the force of the ultrasonic wave and collected at the node of sound pressure.  Consequently, the layer of the microparticles flowing down to the position, where the suction pipe 171 is located, is separated from the layer of the solvent.
Participants in this group will receive MEPILEX POST OP BORDER, a 4-layer foam dressing with flex technology. This advanced dressing is designed to provide superior absorption and conformability, helping to manage exudate and protect the wound site. The dressing will be applied post-operatively and changed as per the standardized protocol.
Provided is a pruritus-alleviating sheet having an excellent pruritus-alleviating effect. A pruritus-alleviating sheet 1 covers a pruritic lesion and comprises a permeable layer 10, a nonpermeable layer 20, and a cool-feeling layer 30. The nonpermeable layer 20 is disposed on the permeable layer 10 and the cool-feeling layer 30 is disposed on the nonpermeable layer 20. The permeable layer 10 is a layer impregnated by a drug that controls pruritus. The nonpermeable layer 20 is a layer for preventing permeation of the drug. The cool-feeling layer is a layer having a cool-feeling effect. The pruritus-alleviating sheet 1 covers a lesion such that the permeable layer 10 contacts the lesion.
Root canal instrumentation was performed using the Reciproc Blue (VDW, Munich) #50/0.5 file. During instrumentation of the root canals, irrigation was applied with 10 mL 2.5% NaOCl using side-vented needles. The final irrigation in Control group was applied with 5 ml of 17% EDTA solution and 5 ml of distilled water. The root canals were dried with sterile paper points and were filled with cold lateral condensation technique using AH Plus root canal sealer and gutta percha. Then the cavity entry was restored with composite (Solarex, GC Corparation, Tokyo, Japan) and radiography was taken. The pre-treatment and 24-month follow-up radiographs of teeth, were prepared as a Power Point presentation and the change in periapical radiolucency was assessed according to PAI scores Teeth with a PAI≤ 2 score and clinically asymptomatic were considered 'healthy' in the radiographic evaluation, while teeth with a PAI≥ 3 and/or clinically symptomatic were considered 'failure'.
Two-phase gel compositions are provided. The two-phase gel compositions are obtained by mixing a gelled ester composition comprising a mixture of an ester compound and a polymer compound selected from the group consisting of triblock copolymers, star polymers, radial polymers, multi-block copolymers, and a combination thereof and a hydrophobic, non polar solvent.  The gelled ester has a viscosity .eta.1 and the solvent has a viscosity .eta.2. The two-phase get composition is substantially free of phosphate compounds and has a viscosity .eta. which is greater than or equal to .eta.1 and which is greater than or equal to .eta.2. The two-phase gel compositions may be used to suspend various solids, liquids and/or gases.
FIELD: chemistry.SUBSTANCE: invention relates to an antiperspirant and/or deodorant composition containing a carrier, an antiperspirant and/or deodorant active substance, one or two surfactants and a preserving agent. Described is the use of an antiperspirant and/or deodorant composition for reducing IL-1α release and skin irritation, where composition contains 60 wt. % to 95 wt. % of carrier in terms of total weight of antiperspirant and/or deodorant composition, wherein carrier consists of water; from 2 wt. % to 25 wt. % antiperspirant and/or deodorant active substance based on total weight of antiperspirant and/or deodorant composition, where the antiperspirant and/or deodorant active substance is an aluminium-containing antiperspirant and/or deodorant active substance; from 1 wt. % to 7 wt. % surfactant in terms of total weight of antiperspirant and/or deodorant composition, where surfactant provides one or more surfactants with low HLB and one or more surfactants with high HLB and where one or more surfactants with a low HLB are characterized by a HLB value of 3 to 6 and one or more surfactants with a high HLB are characterized by a HLB value of 12 to 16, and from 0.1 wt. % to 0.5 wt. % preservative in terms of total weight of the antiperspirant and/or deodorant composition, where the preserving agent contains at least one of phenoxyethanol, caprylyl glycol, ethylhexyl glycerol, citric acid, benzoic acid, lactic acid and combinations thereof.EFFECT: technical result is creation of antiperspirant and/or deodorant compositions with minimum quantity of ingredients, which maintain the required levels of stability, efficiency and aesthetic characteristics.16 cl, 2 ex, 9 tbl
Tai Chi Chuan (TCC) is a traditional Oriental conditioning exercise or calisthenics that is believed by many people around the world to be good for the health. The frequently claimed reason for this merit of TCC is that it can improve the cardiopulmonary function and immunity of the subject who practice it continuously. TCC has been shown to delay the decline of aerobic power, improve the cardiopulmonary function, balance and strength of the subjects. One study has demonstrated that TCC could reduce tension, anxiety, and mood disturbance. However, few studies have examined the effect of TCC on the blood lipid profile and immunity of the TCC practitioners. Another study reported that 12-week programme of regular TCC exercise enhanced functional mobility, personal health expectations, and regulatory T cell function. It has also been shown that an appropriate combination of TCC exercise program with diabetic medication might improve both glucose metabolism and immunity in type 2 diabetic patients. Since TCC training has been shown to be beneficial to the cardiopulmonary function of the subject, TCC may also have an effect on the blood lipid profile and immunity of the subjects. We hypothesize that TCC might have a beneficial effect on the pulmonary function, autonomic nervous modulation, lipid profile, and cytokines production in the aged subjects. Thus, the aim of this study was to examine whether or not TCC have these effects in the aged subjects.
A live vaccine against vesical eruptions in cattle from infectious pustular vulvovaginitis (IPV, = bovine vesicular coital exanthema) and used in the treatment of diseases of cattle arising from viruses of infectious bovine rhinotracheitis (IBR) and IPV and which is harmless and of universal applicaton is prepd. by tissue culture passages of an electrophoretically homogeneous virus population from an IPV source. The vaccine may be prepd. from any bovine animal tissue specially suitable are calf kidneys, adrenals and epididymis. Culture is at 37-39 degrees in a suitable medium and after the appearance of the cytopathogenic effect as shown by 80-100 degrees destruction of the cell culture (about 24-48 hrs.) the centrifuged supernatant may be used direct as a vaccine or after lyophilisation and re-solution.
Pregnant or recently pregnant women 18 years of age and older treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 at any time during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
BACKGROUND: The utilization of short humeral stems in reverse total shoulder arthroplasty has gained attention in recent times. However, concerns regarding the risk of misalignment during implant insertion are associated with their use.
METHODS: Eight fresh-frozen cadaveric shoulders were prepared for dissection and biomechanical testing. A bespoke humeral implant was fabricated to facilitate assessment of neutral, varus, and valgus alignments using a single stem, and 10° was established as the maximum permissible angle for misalignments. Shift in humerus position and changes in deltoid length attributable to misalignments relative to the neutral position were evaluated using a Microscribe 3DLx system. The impingement-free range of motion, encompassing abduction, adduction, internal rotation, and external rotation (ER), was gauged using a digital goniometer. The capacity for abduction was evaluated at maximal abduction angles under successive loading on the middle deltoid. A specialized traction system coupled with a force transducer was employed to measure anterior dislocation forces.
RESULTS: Relative to the neutral alignment, valgus alignment resulted in a more distal (10.5 ± 2.4 mm) and medial (8.3 ± 2.2 mm) translation of the humeral component, whereas the varus alignment resulted in the humerus shifting more superiorly (11.2 ± 1.3 mm) and laterally (9.9 ± 0.9 mm) at 0° abduction. The valgus alignment exhibited the highest abduction angle than neutral alignment (86.2°, P < .001). Conversely, the varus alignment demonstrated significantly higher adduction (18.4 ± 7.4°, P < .001), internal rotation (68.9 ± 15.0°, P = .014), and ER (45.2 ± 10.5°, P = .002) at 0° abduction compared to the neutral alignments. Anterior dislocation forces were considerably lower (23.8 N) in the varus group compared to the neutral group at 0°ER (P = .047). Additionally, abduction capability was markedly higher in varus alignment at low deltoid loads than the neutral alignment (5N, P = .009; 7.5 N, P = .007).
CONCLUSIONS: The varus position enhances rotational range of motion (ROM) but increases instability, while the valgus position does not significantly impact ROM or instability compared to the neutral position.
Research staff will record the brain activity of subjects by using an electroencephalogram (EEG), a device that measures the electrical activity in the brain through electrodes put on the scalp. There is no risk of electrical shock. Research staff will put a cap on the subject's head that has electrodes that will measure your brain activity. In addition to the electrodes in the cap, two electrode clips will be put on your ears. EEG activity will be collected for 20 minutes: subjects will have their eyes open for ten minutes, and then eyes closed for ten minutes.

Before the assessment, subjects will be asked how much pain they are currently in. Once the 20-minute assessment has ended, the research staff member will again ask subjects how much pain they are currently in, and how much pain they had during the EEG assessment. Subjects with SCI-related pain on a daily basis may also be contacted in the future to see if they want to participate in the second phase of this study that will involve learning to directly change their brain activity.
After performing lateral lymph node dissection for the enrolled patients, we would find the targeted lateral node which was matched with the enlarged one in imaging from the specimen. Then the nodes would be send for pathological examination. Then we would extract the radiomics parameters of the nodes from the pretreatment CT and MRI with ITK-SNAP software. According to the pathological status, lymph nodes and corresponding radiomics parameters would be divided into positive and negative groups. Then significant parameters would be selected by R software. Then the prediction model with nomogram would be developed. 70% nodes would be used for for model development and the other 30% would be used for validation.